Frideborg Bradley1, Kenzie Birse2,3, Klara Hasselrot1,4, Laura Noël-Romas2,3, Andrea Introini1, Hugo Wefer5,6, Maike Seifert5,6, Lars Engstrand5,6, Annelie Tjernlund1, Kristina Broliden1, Adam D Burgener1,2,3. 1. Department of Medicine Solna, Unit of Infectious Diseases, Center for Molecular Medicine, Karolinska Institutet Karolinska University Hospital, Stockholm, Sweden. 2. Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada. 3. National HIV and Retrovirology Labs, JC Wilt Infectious Disease Centre, Public Health Agency of Canada, Winnipeg, MB, Canada. 4. Department of Gynaecology, Danderyds Hospital, Stockholm, Sweden. 5. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. 6. Science for Life Laboratory, Clinical Genomics Facility, Solna, Sweden.
Abstract
PROBLEM: Susceptibility to HIV is associated with the menstrual cycle and vaginal microbiome, but their collective impact on vaginal inflammation remains unclear. Here, we characterized the cervicovaginal proteome, inflammation, and microbiome community structure and function during the menstrual cycle. METHOD OF STUDY: Cervicovaginal secretions were collected from regularly cycling women (n = 16) at median day 10, 16, and 24 of each menstrual cycle and analyzed by mass spectrometry, 16S rRNA gene sequencing, and a multiplex bead array immunoassay. Follicular, ovulatory, and luteal phases were defined by serum sex hormone levels. RESULTS: Ovulation showed the largest mucosal proteome changes, where 30% and 19% of the 406 human proteins identified differed compared to the luteal and follicular phases, respectively. Neutrophil/leukocyte migration pathways were lowest during ovulation and peaked in the luteal phase, while antimicrobial and epithelial barrier promoting proteins were highest during ovulation. Vaginal microbial community structure and function did not vary significantly during the menstrual cycle, with the majority consistently Lactobacillus-dominant (63%) or non-Lactobacillus-dominant (25%). Fluctuations in the epithelial barrier protein RPTN between the ovulatory and luteal phase were amplified in women with Gardnerella vaginalis and anaerobic bacteria and reduced when Lactobacillus was dominant. CONCLUSION: This small study demonstrates that sex hormones modulate neutrophil/leukocyte inflammation, barrier function, and antimicrobial pathways in the female genital tract with the strongest changes occurring during ovulation. The data further suggest a microbiome context for hormone-driven changes in vaginal immunity which may have implications for HIV susceptibility.
PROBLEM: Susceptibility to HIV is associated with the menstrual cycle and vaginal microbiome, but their collective impact on vaginal inflammation remains unclear. Here, we characterized the cervicovaginal proteome, inflammation, and microbiome community structure and function during the menstrual cycle. METHOD OF STUDY: Cervicovaginal secretions were collected from regularly cycling women (n = 16) at median day 10, 16, and 24 of each menstrual cycle and analyzed by mass spectrometry, 16S rRNA gene sequencing, and a multiplex bead array immunoassay. Follicular, ovulatory, and luteal phases were defined by serum sex hormone levels. RESULTS: Ovulation showed the largest mucosal proteome changes, where 30% and 19% of the 406 human proteins identified differed compared to the luteal and follicular phases, respectively. Neutrophil/leukocyte migration pathways were lowest during ovulation and peaked in the luteal phase, while antimicrobial and epithelial barrier promoting proteins were highest during ovulation. Vaginal microbial community structure and function did not vary significantly during the menstrual cycle, with the majority consistently Lactobacillus-dominant (63%) or non-Lactobacillus-dominant (25%). Fluctuations in the epithelial barrier protein RPTN between the ovulatory and luteal phase were amplified in women with Gardnerella vaginalis and anaerobic bacteria and reduced when Lactobacillus was dominant. CONCLUSION: This small study demonstrates that sex hormones modulate neutrophil/leukocyte inflammation, barrier function, and antimicrobial pathways in the female genital tract with the strongest changes occurring during ovulation. The data further suggest a microbiome context for hormone-driven changes in vaginal immunity which may have implications for HIV susceptibility.
Authors: Anna Månberg; Frideborg Bradley; Ulrika Qundos; Brandon L Guthrie; Kenzie Birse; Laura Noël-Romas; Cecilia Lindskog; Rose Bosire; James Kiarie; Carey Farquhar; Adam D Burgener; Peter Nilsson; Kristina Broliden Journal: Mol Cell Proteomics Date: 2018-11-30 Impact factor: 5.911
Authors: Annabel S Hinderfeld; Niha Phukan; Ann-Katrein Bär; Anthony M Roberton; Augusto Simoes-Barbosa Journal: Infect Immun Date: 2019-04-23 Impact factor: 3.441
Authors: Michelle D Cherne; Amy L Cole; Lisa Newberry; Mary Schmidt-Owens; Michael Deichen; Alexander M Cole Journal: Infect Immun Date: 2020-03-23 Impact factor: 3.441
Authors: Hilary O D Critchley; Elnur Babayev; Serdar E Bulun; Sandy Clark; Iolanda Garcia-Grau; Peter K Gregersen; Aoife Kilcoyne; Ji-Yong Julie Kim; Missy Lavender; Erica E Marsh; Kristen A Matteson; Jacqueline A Maybin; Christine N Metz; Inmaculada Moreno; Kami Silk; Marni Sommer; Carlos Simon; Ridhi Tariyal; Hugh S Taylor; Günter P Wagner; Linda G Griffith Journal: Am J Obstet Gynecol Date: 2020-07-21 Impact factor: 10.693
Authors: Salwan Al-Nasiry; Elena Ambrosino; Melissa Schlaepfer; Servaas A Morré; Lotte Wieten; Jan Willem Voncken; Marialuigia Spinelli; Martin Mueller; Boris W Kramer Journal: Front Immunol Date: 2020-03-16 Impact factor: 7.561